Literature DB >> 18110807

Preliminary report on clinical trials of antabuse.

R G BELL, H W SMITH.   

Abstract

Keywords:  ANTABUSE

Mesh：

Substances：

Year:  1949        PMID： 18110807      PMCID： PMC1591479     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN： 0008-4409            Impact factor:   8.262


× No keyword cloud information.
  12 in total

1.  Death following the ingestion of alcohol in an antabuse treated patient.

Authors:  R O JONES
Journal:  Can Med Assoc J       Date:  1949-06       Impact factor: 8.262

Review 2.  Managing temptation in obesity treatment: A neurobehavioral model of intervention strategies.

Authors:  Bradley M Appelhans; Simone A French; Sherry L Pagoto; Nancy E Sherwood
Journal:  Appetite       Date:  2015-10-22       Impact factor: 3.868

Review 3.  Targeting aldehyde dehydrogenase 2: new therapeutic opportunities.

Authors:  Che-Hong Chen; Julio Cesar Batista Ferreira; Eric R Gross; Daria Mochly-Rosen
Journal:  Physiol Rev       Date:  2014-01       Impact factor: 37.312

Review 4.  Aldehyde dehydrogenase inhibitors: a comprehensive review of the pharmacology, mechanism of action, substrate specificity, and clinical application.

Authors:  Vindhya Koppaka; David C Thompson; Ying Chen; Manuel Ellermann; Kyriacos C Nicolaou; Risto O Juvonen; Dennis Petersen; Richard A Deitrich; Thomas D Hurley; Vasilis Vasiliou
Journal:  Pharmacol Rev       Date:  2012-04-27       Impact factor: 25.468

5.  Disulfiram blocked cell entry of SARS-CoV-2 via inhibiting the interaction of spike protein and ACE2.

Authors:  Hsiao-Fan Chen; Po-Ren Hsueh; Yen-Yi Liu; Yeh Chen; Sui-Yuan Chang; Wei-Jan Wang; Chen-Shiou Wu; Ya-Min Tsai; Yu-Shu Liu; Wen-Chi Su; Yu-Chi Chou; Mien-Chie Hung
Journal:  Am J Cancer Res       Date:  2022-07-15       Impact factor: 5.942

Review 6.  Connecting copper and cancer: from transition metal signalling to metalloplasia.

Authors:  Eva J Ge; Ashley I Bush; Angela Casini; Paul A Cobine; Justin R Cross; Gina M DeNicola; Q Ping Dou; Katherine J Franz; Vishal M Gohil; Sanjeev Gupta; Stephen G Kaler; Svetlana Lutsenko; Vivek Mittal; Michael J Petris; Roman Polishchuk; Martina Ralle; Michael L Schilsky; Nicholas K Tonks; Linda T Vahdat; Linda Van Aelst; Dan Xi; Peng Yuan; Donita C Brady; Christopher J Chang
Journal:  Nat Rev Cancer       Date:  2021-11-11       Impact factor: 69.800

Review 7.  Aldehyde Dehydrogenase 1 making molecular inroads into the differential vulnerability of nigrostriatal dopaminergic neuron subtypes in Parkinson's disease.

Authors:  Huaibin Cai; Guoxiang Liu; Lixin Sun; Jinhui Ding
Journal:  Transl Neurodegener       Date:  2014-12-10       Impact factor: 8.014

Review 8.  A Critical Review of the Evidence Concerning the HIV Latency Reversing Effect of Disulfiram, the Possible Explanations for Its Inability to Reduce the Size of the Latent Reservoir In Vivo, and the Caveats Associated with Its Use in Practice.

Authors:  Harry D J Knights
Journal:  AIDS Res Treat       Date:  2017-03-30

9.  Anti-alcohol abuse drug disulfiram inhibits human PHGDH via disruption of its active tetrameric form through a specific cysteine oxidation.

Authors:  Quentin Spillier; Didier Vertommen; Séverine Ravez; Romain Marteau; Quentin Thémans; Cyril Corbet; Olivier Feron; Johan Wouters; Raphaël Frédérick
Journal:  Sci Rep       Date:  2019-03-18       Impact factor: 4.379

10.  Disulfiram can inhibit MERS and SARS coronavirus papain-like proteases via different modes.

Authors:  Min-Han Lin; David C Moses; Chih-Hua Hsieh; Shu-Chun Cheng; Yau-Hung Chen; Chiao-Yin Sun; Chi-Yuan Chou
Journal:  Antiviral Res       Date:  2017-12-28       Impact factor: 5.970
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.